Efficacy of Docetaxel (J 15) and Celecoxib in Metastatic Prostate Cancer
Association Docetaxel (J 15) and celecoxib Patient survival Biological parameter : PSA
Clinical status RECIST evaluation
Observational
Time Perspective: Prospective
Christian PFISTER, MD, PhD
Principal Investigator
University Hospital, Rouen
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
2003/052/HP
NCT00213694
November 2003
June 2006
Name | Location |
---|